TORONTO, June 23, 2011 /CNW/ - An economic strategy to ensure the sustainability and success of Ontario's commercial bioscience sector was announced today. Implementation of the strategy is underway, according to OBIO™, the CEO-led industry organization.
Developed by multi-stakeholder Ontario Bioscience Economic Strategy (OBEST™) teams in seven regional bioscience clusters, the strategy comprises nine priority initiatives. Of these, five are for implementation by the industry; four will be implemented by the industry partnering with government.
Dr. Daniel Billen, Chair of the OBEST Advisory Board and General Manager, Amgen Canada, said: "We have put the onus on our industry to implement this strategy and on government to put supportive policies in place. Together, these will enable Ontario's bioscience companies to complete the virtuous cycle of economic growth, jobs and improved health for all."
To read the full, original article click on this link: ONTARIO BIOSCIENCE INDUSTRY ORGANIZATION | Nine-point strategy for growth and sustainability of Ontario bioscience industry is launched
